Press Releases

Press Releases

Date Title and Summary Additional Formats
Feb 07, 2022 Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update
2021 Total Revenues Estimated at $141 Million , Representing 18% YoY Growth Forecast 2022 Total Revenues of Between $195 Million and $205 Million , Representing YoY Growth of 38% to 45% Recently Regained Orphan Drug Exclusivity in the U.S. for Amifampridine to Treat LEMS Entering 2022 with a Strong
Feb 03, 2022 Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid
Earlier this Week the District Court Granted Summary Judgement to Catalyst in Its Lawsuit Against the FDA and this FDA Action is the Result of that Decision CORAL GABLES, Fla. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage,
Jan 28, 2022 Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst
CORAL GABLES, Fla. , Jan. 28, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare
Jan 10, 2022 Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing
CORAL GABLES, Fla. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare
Jan 04, 2022 Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences
CORAL GABLES, Fla. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals , Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare

Displaying 11 - 15 of 15